

PRESS RELEASE

Positive interim analysis of BioPhausia's Krillase® study

An interim analysis of the ongoing clinical trials in Europe using Krillase® for debridement of chronic wounds has been made. The analysis is based on data from a third of the planned number of patients.

The analysis supports the earlier hypothesis on expected clinical effects between Krillase® and the comparators used in the study. No extension of the clinical program is therefore required before application for registration.

Stellan Lind, President: "We are extremely pleased with this report. Today two thirds of the planned number of patients are included in the study, and we expect the final result to be reported during the third quarter of 1998".

Uppsala, February 6, 1998.

BioPhausia conducts research and development primarily in connective tissue biology, aiming at introducing pharmaceuticals with well defined clinical and pharmacoeconomic advantages. Marketing will be done through outlicensing to companies with strong franchises with respective customer segment.

The project portfolio includes the resuscitation solution RescueFlow®; the application for registration has been submitted both in the US and in Europe, Krillase®, for the debridement of chronic wounds, in clinical trials phase III. The portfolio also includes a project pertaining to hyaluronidase in edema reduction treatment, a tumour project where the aim is to achieve more effective cytotoxic drug treatment, as well as a project relating to organ transplantation solutions.

For further information at BioPhausia, please contact:

Stellan Lind, President, or
Dr. Bertil Karlmark, Medical Director.
Tel. +46 (0) 18-34 99 00